Independent Aventiv Research Selected by Pfizer & BioNTech for COVID-19 Vaccine Trial: Volunteers Drive 2 Hours to Contribute

Independently-owned Columbus Ohio-based Aventiv Research was selected by the Pfizer/BioNTech “Project Lightspeed” program to participate in the Phase 2/3 clincial trial to test the RNA-based COVID-19 vaccine. With involvement of 120 sites around the world, this...

UC Davis Health Ramps Up Project Lightspeed: Serves as Trial Site for Phase 2/3 BNT162 COVID-19 Vaccine Study

UC Davis Health was one of about 120 trial sites selected worldwide to participate in the Phase 2/3 stage testing of the COVID-19 vaccine candidate known as BTN162, developed by Germany’s BioNTech and Pfizer Inc. The addition of this pivotal clinical trial adds even a...

Pin It on Pinterest